We are monitoring the impact of COVID-19 on Latin America Checkpoint Inhibitors Market Get in touch with us for detailed analysis Know More
Share on

Latin America Checkpoint Inhibitors Market Research Report – Segmented By Type, Application & Country (Mexico, Brazil, Argentina, Chile and Rest of Latin America) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2022 to 2027)

Published: January, 2022
ID: 2088
Pages: 145

Latin America Checkpoint Inhibitors Market Size (2022 to 2027)

The size of the Checkpoint Inhibitors Market in Latin America was valued at USD 1.81 million in 2022. It is further expected to reach USD 6.51 billion by 2027, growing at a CAGR of 29.2 % during the forecast period.

Checkpoint inhibitors are cancer medicines that target the checkpoints. As a result, the market for checkpoint inhibitors is expected to grow as cancer incidence rates rise.

The checkpoint inhibitors market in Latin American is estimated to be driven by the sharp rise in various types of malignancies, as well as a sharp rise in the geriatric population in Latin America, particularly in industrialized and rising economies. In addition, during the forecast period, the increase in the number of cancer cases in Latin America is expected to contribute to the growth of the checkpoint inhibitors market. Lung, prostate, bowel, and female breast cancer are the four most frequent kinds of cancer, accounting for 43 percent of all new cancer cases.

Increased cancer prevalence in Latin America, high demand for ideal therapeutics for cancer treatment, favorable reimbursement policies offered by manufacturers and insurance providers in some countries, and increased awareness of checkpoint inhibitors for cancer treatment due to positive results are the main factors driving the growth of the Latin American checkpoint inhibitors market.

However, the Latin American checkpoint inhibitor market is projected to be hampered by the high cost of cancer therapy using checkpoint inhibitors. There is a lot of pressure to keep expenses down and show value. Political uncertainty and ongoing economic stress are putting public health care funding in jeopardy in several countries. The lack of cost-effective cancer medicines has influenced the population's health and resulted in poor life expectancy. A course of intravenous checkpoint inhibitor medication, for example, costs between $150,000 and $250,000, which is too expensive, especially in nations without public health care. As a result of the high cost of checkpoint inhibitor cancer treatment, the checkpoint inhibitor market is projected to be limited.

This research report on the Latin America checkpoint inhibitors market has been segmented and sub-segmented into the following categories.

By Drug: 

  • PD-1 inhibitors
  • PD-L1 inhibitors
  • CTLA-4
  • Chimeric Antigen Receptor T-cell
  • Others

By Application: 

  • Lung cancer
  • Renal cancer
  • Blood cancer
  • Bladder Cancer
  • Hodgkin lymphoma
  • Melanoma
  • Others

By Country: 

  • Brazil
  • Argentina
  • Mexico
  • Chile
  • Rest of Latin America

Latin America is predicted to have a moderate share of the global checkpoint inhibitors market during the forecast period. Mexico and Brazil have the largest market share in Latin America.  During the forecast period, the presence of a large population of baby boomers in Mexico necessitated the efficient treatment of various chronic diseases such as diabetes, skin cancer, urothelial carcinomas, and lung cancers, as well as the growing prevalence of various chronic diseases such as diabetes, skin cancer, urothelial carcinomas, and lung cancers.

KEY MARKET PLAYERS:

Merck & Co., Inc., Bristol-Myers Squibb, Roche, AstraZeneca, Ono Pharmaceutical Co., Ltd., Juno Therapeutics, and others play an influential role in the Latin America checkpoint inhibitors market Novartis International AG, and Kite Pharma.

1.Introduction                                                                  

                1.1 Market Definition                                                    

                1.2 Study Deliverables                                                  

                1.3 Base Currency, Base Year and Forecast Periods                                                          

                1.4 General Study Assumptions                                                

2. Research Methodology                                                                           

                2.1 Introduction                                                               

                2.2 Research Phases                                                      

                                2.2.1 Secondary Research                                           

                                2.2.2 Primary Research                                 

                                2.2.3 Econometric Modelling                                      

                                2.2.4 Expert Validation                                  

                2.3 Analysis Design                                                         

                2.4 Study Timeline                                                          

3. Overview                                                                       

                3.1 Executive Summary                                                

                3.2 Key Inferences                                                         

                3.3 Epidemology                                                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                                                    

                4.1 Market Drivers                                                          

                4.2 Market Restraints                                                    

                4.3 Key Challenges                                                         

                4.4 Current Opportunities in the Market                                                              

5. Market Segmentation                                                                              

                5.1 Drug Type                                                   

                                5.1.1 Introduction                                           

                                5.1.2 PD-1 inhibitors                                       

                                5.1.3 PD-L1 inhibitors                                     

                                5.1.4 CTLA-4                                      

                                5.1.5  Chimeric Antigen Receptor T-cell                                 

                                5.1.6  Others                                     

                                5.1.7 Y-o-Y Growth Analysis, By Drug Type                                           

                                5.1.8 Market Attractiveness Analysis, By Drug Type                                         

                                5.1.9 Market Share Analysis, By Drug Type                                          

                5.2 Application                                                 

                                5.2.1 Introduction                                           

                                5.2.2 Lung cancer                                            

                                5.2.3 Renal cancer                                           

                                5.2.4 Blood cancer                                          

                                5.2.5 Bladder Cancer                                      

                                5.2.6  Hodgkin lymphoma                                            

                                5.2.7 Melanoma                                              

                                5.2.8  Others                                     

                                5.2.9 Y-o-Y Growth Analysis, By Application                                         

                                5.2.10  Market Attractiveness Analysis, By Application                                   

                                5.2.11  Market Share Analysis, By Application                                     

6. Geographical Analysis                                                                              

                6.1 Introduction                                                               

                                6.1.1 Regional Trends                                    

                                6.1.2 Impact Analysis                                     

                                6.1.3 Y-o-Y Growth Analysis                                        

                                                6.1.3.1 By Geographical Area                     

                                                6.1.3.2 By Drug Type                      

                                                6.1.3.3 By Application                    

                                6.1.4  Market Attractiveness Analysis                                     

                                                6.1.4.1 By Geographical Area                     

                                                6.1.4.2 By Drug Type                      

                                                6.1.4.3 By Application                    

                                6.1.5  Market Share Analysis                                      

                                                6.1.5.1 By Geographical Area                     

                                                6.1.5.2 By Drug Type                      

                                                6.1.5.3 By Application                    

                6.2 Brazil                                                             

                6.3 Mexico                                                         

                6.4 Rest of Latin America                                                             

7.Strategic Analysis                                                                        

                7.1 PESTLE analysis                                                         

                                7.1.1 Political                                     

                                7.1.2 Economic                                 

                                7.1.3 Social                                         

                                7.1.4 Technological                                         

                                7.1.5 Legal                                          

                                7.1.6 Environmental                                       

                7.2 Porter’s Five analysis                                                              

                                7.2.1 Bargaining Power of Suppliers                                        

                                7.2.2 Bargaining Power of Consumers                                    

                                7.2.3 Threat of New Entrants                                     

                                7.2.4 Threat of Substitute Products and Services                                              

                                7.2.5 Competitive Rivalry within the Industry                                     

8.Market Leaders' Analysis                                                                         

                8.1 Merck & Co., Inc.                                                     

                                8.1.1 Overview                                 

                                8.1.2 Product Analysis                                   

                                8.1.3 Financial analysis                                  

                                8.1.4 Recent Developments                                       

                                8.1.5 SWOT analysis                                       

                                8.1.6 Analyst View                                          

                8.2 Bristol-Myers Squibb                                                              

                8.3 Roche                                                           

                8.4 AstraZeneca                                                               

                8.5 Ono Pharmaceutical Co., Ltd.                                                              

                8.6  Juno Therapeutics                                                  

                8.7 Novartis International AG                                                    

                8.8 Kite Pharma                                                               

9.Competitive Landscape                                                                            

                9.1 Market share analysis                                                            

                9.2 Merger and Acquisition Analysis                                                       

                9.3 Agreements, collaborations and Joint Ventures                                                         

                9.4 New Product Launches                                                         

10.Market Outlook and Investment Opportunities                                                                          

Appendix                                                                           

                a) List of Tables                                                

                b) List of Figures                                                              

  1. Latin America Checkpoint Inhibitors Market, By Drug Type, From 2022 - 2027 (USD Billion)
  2. Latin America PD-1 inhibitors Market, By Region, From 2022 - 2027 (USD Billion)
  3. Latin America PD-L1 inhibitors Market, By Region, From 2022 - 2027 (USD Billion)
  4. Latin America CTLA-4 Market, By Region, From 2022 - 2027 (USD Billion)
  5. Latin America Chimeric Antigen Receptor T-cell Market, By Region, From 2022 - 2027 (USD Billion)
  6. Latin America Others Market, By Region, From 2022 - 2027 (USD Billion)
  7. Latin America Checkpoint Inhibitors Market, By Application, From 2022 - 2027 (USD Billion)
  8. Latin America Lung cancer Market, By Region, From 2022 - 2027 (USD Billion)
  9. Latin America Renal cancer Market, By Region, From 2022 - 2027 (USD Billion)
  10. Latin America Blood cancer Market, By Region, From 2022 - 2027 (USD Billion)
  11. Latin America Bladder Cancer Market, By Region, From 2022 - 2027 (USD Billion)
  12. Latin America Hodgkin lymphoma Market, By Region, From 2022 - 2027 (USD Billion)
  13. Latin America Melanoma Market, By Region, From 2022 - 2027 (USD Billion)
  14. Latin America Others Market, By Region, From 2022 - 2027 (USD Billion)
  15. Brazil Checkpoint Inhibitors Market, By Drug Type, From 2022 - 2027 (USD Billion)
  16. Brazil Checkpoint Inhibitors Market, By Application, From 2022 - 2027 (USD Billion)
  17. Argentina Checkpoint Inhibitors Market, By Drug Type, From 2022 - 2027 (USD Billion)
  18. Argentina Checkpoint Inhibitors Market, By Application, From 2022 - 2027 (USD Billion)
  19. Mexico Checkpoint Inhibitors Market, By Drug Type, From 2022 - 2027 (USD Billion)
  20. Mexico Checkpoint Inhibitors Market, By Application, From 2022 - 2027 (USD Billion)
  21. Rest of Latin America Checkpoint Inhibitors Market, By Drug Type, From 2022 - 2027 (USD Billion)
  22. Rest of Latin America Checkpoint Inhibitors Market, By Application, From 2022 - 2027 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

2875


pdf excel
$

3220


pdf excel powerbi
$

4600


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2875

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample